10x Genomics (TXG) Change in Acquisitions & Divestments (2022 - 2025)
10x Genomics (TXG) has disclosed Change in Acquisitions & Divestments for 4 consecutive years, with $125.2 million as the latest value for Q4 2025.
- Quarterly Change in Acquisitions & Divestments rose 671.01% to $125.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $125.2 million through Dec 2025, up 3146.89% year-over-year, with the annual reading at $125.2 million for FY2025, 3146.89% up from the prior year.
- Change in Acquisitions & Divestments hit $125.2 million in Q4 2025 for 10x Genomics, up from -$50.0 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $125.2 million in Q4 2025 to a low of -$50.0 million in Q3 2025.
- Historically, Change in Acquisitions & Divestments has averaged $17.7 million across 4 years, with a median of $12.9 million in 2024.
- Biggest YoY gain for Change in Acquisitions & Divestments was 12658.4% in 2023; the steepest drop was 176.26% in 2023.
- Year by year, Change in Acquisitions & Divestments stood at -$22.9 million in 2022, then skyrocketed by 230.55% to $29.9 million in 2023, then crashed by 173.43% to -$21.9 million in 2024, then soared by 671.01% to $125.2 million in 2025.
- Business Quant data shows Change in Acquisitions & Divestments for TXG at $125.2 million in Q4 2025, -$50.0 million in Q3 2025, and $50.0 million in Q2 2025.